Operabl Meme Kanserli Hastalarda Adjuvan Sistemik Tedavinin Rolü
References
Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012 Feb 4;379(9814):432. doi:10.1016/S0140-6736(11)61625-5 PubMed PMID: 22152853.
Rashmi Kumar N, Schonfeld R, Gradishar WJ, Lurie RH, Moran MS, Abraham J, et al. NCCN Guidelines Version 1.2026 Breast Cancer [Internet]. 2026. Available from: https://www.nccn.org/
De Almeida FK, Rosa DD. Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates. Breast Care. 2018 Dec 1;13(6):447. doi:10.1159/000488026 PubMed PMID: 30800040.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013;381(9869):805–16. doi:10.1016/S0140-6736(12)61963-1 PubMed PMID: 23219286.
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987–98. doi:10.1200/JCO.20.02514 PubMed PMID: 32954927.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):111–21. doi:10.1056/NEJMOA1804710 PubMed PMID: 29860917.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 Dec 16;385(25):2336–47. doi:10.1056/NEJMOA2108873 PubMed PMID: 34914339.
Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. New England Journal of Medicine. 2016 Aug 25;375(8):717–29. doi:10.1056/NEJMOA1602253/SUPPL_FILE/NEJMOA1602253_DISCLOSURES.PDF PubMed PMID: 27557300.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine. 2019 Feb 14;380(7):617–28. doi:10.1056/nejmoa1814017 PubMed PMID: 30516102.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine. 2017 Jun 1;376(22):2147–59. doi:10.1056/NEJMOA1612645/SUPPL_FILE/NEJMOA1612645_DISCLOSURES.PDF PubMed PMID: 28564564.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2024 Feb 1;35(2):159–82. doi:10.1016/J.ANNONC.2023.11.016/ATTACHMENT/AE650DFD-CEDF-47E9-B303-96D0D731B1B0/MMC1.PDF PubMed PMID: 38101773.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine. 2018 Jul 12;379(2):122–37. doi:10.1056/NEJMOA1803164/SUPPL_FILE/NEJMOA1803164_DISCLOSURES.PDF PubMed PMID: 29863451.
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 2016 Jul 21;375(3):209–19. doi:10.1056/nejmoa1604700 PubMed PMID: 27264120.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine. 2024 Mar 21;390(12):1080–91. doi:10.1056/NEJMOA2305488/SUPPL_FILE/NEJMOA2305488_DATA-SHARING.PDF PubMed PMID: 38507751.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020 Feb 27;382(9):810–21. doi:10.1056/NEJMOA1910549/SUPPL_FILE/NEJMOA1910549_DATA-SHARING.PDF PubMed PMID: 32101663.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10;396(10257):1090–100. doi:10.1016/S0140-6736(20)31953-X PubMed PMID: 32966830.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer . New England Journal of Medicine. 2021 Jun 24;384(25):2394–405. doi:10.1056/nejmoa2105215 PubMed PMID: 34081848.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine. 2005 Oct 20;353(16):1659–72. doi:10.1056/NEJMOA052306/SUPPL_FILE/NEJM_PICCART_1659SA1-2.PDF PubMed PMID: 16236737.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. 2017 Jul 13;377(2):122–31. doi:10.1056/NEJMOA1703643/SUPPL_FILE/NEJMOA1703643_DISCLOSURES.PDF PubMed PMID: 28581356.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec 1;18(12):1688–700. doi:10.1016/S1470-2045(17)30717-9 PubMed PMID: 29146401.
Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019 Oct 1;5(10):1473–8. doi:10.1001/JAMAONCOL.2019.1838 PubMed PMID: 31369045.
Loi S, Johnston SRD, Arteaga CL, Graff SL, Chandarlapaty S, Goetz MP, et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Journal of Clinical Oncology. 2024 Jun 10;42(17_suppl):LBA507–LBA507. doi:10.1200/JCO.2024.42.17_SUPPL.LBA507
